Navigation Links
Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Date:5/12/2008

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Emphasys Medical Inc., today announced that one-year data from the VENT clinical trial of the company's Zephyr(R) Endobronchial Valve (EBV) will be presented at the International Conference of the American Thoracic Society (ATS) occurring May 16 to 21 in Toronto, Canada.

Sunday, May 18, 9:30-11:00 a.m. (ET), Metro Toronto Convention Centre, Room 801A

In the symposium, "Innovations in Emphysema Treatment: Lung Volume Reduction and Lung Volume Reduction Surgery," Zephyr related presentations include:

-- Frank Sciurba, M.D., University of Pittsburgh Medical Center, the

principal investigator of VENT, will present on the Durability of

Endobronchial Valve Effect on Lung Function at 6 and 12 Months.

-- Jonathan Goldin, M.D., Ph.D., University of California at Los Angeles,

the principal investigator of the VENT radiology core lab, will

present on Fissure Integrity As a Marker of Collateral Ventilation

Across Lung Lobes.

-- Jim Egan, M.D., Mater Misericordiae Hospital, Dublin, Ireland, will

present on the Treatment of Advanced Emphysema by Endoscopic Volume

Reduction.

-- John Travaline, M.D., Temple University, will present on the Efficacy

of Endobronchial Valves in the Treatment of Persistent Air Leaks.

Monday, May 19, 8:30 a.m., Metro Toronto Convention Centre, Room 715A

-- Charlie Strange, M.D., Medical University of South Carolina will

present on the relation of FEV1/FVC and Fissure Integrity in the VENT

Study.

Monday, May 19, 3:10 p.m., Metro Toronto Convention Centre, Hall G

-- Frank Sciurba, M.D., will present on Bronchoscopic Methods for

Palliation of Emphysema.

About the Zephyr Endobronchial Valve

The Zephyr EBV is a novel, minimally-invasive device intended to treat emphysema. The Zephyr EBV is designed to isolate diseased, overinflated portions of the lung and cause them to shrink thereby allowing healthier portions of the lung to function more normally.

The Zephyr EBV is CE marked and is commercially available in Europe and other international markets, including Australia, New Zealand, Hong Kong and Singapore. The Zephyr EBV is limited to investigational use in the United States. The company's Premarket Approval Application is currently under review by the U.S. Food and Drug Administration.

About Emphasys Medical

Emphasys Medical (http://www.emphasysmedical.com) is a medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders. Based in Redwood City, California, Emphasys Medical was incubated at The Foundry.


'/>"/>
SOURCE Emphasys Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy
2. MSU engineering team designs innovative medical device
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
6. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
7. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
8. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
9. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
10. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... AUSTIN (PRWEB) , ... February 08, 2016 , ... Remember ... next time. , According to Perry A~, author of “Calcium Bentonite Clay” the ... a key role in balancing and detoxifying the body. , A former motivational speaker, ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's ... organizations. DocuSyst provides a cloud hosted environment for FileHold software that is ... with various 3rd party applications using the FileHold web services API. DocuSyst also ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... DIEGO , Feb. 8, 2016 /PRNewswire/--  Cell ... announced that advanced tissue-engineering services are now available ... a groundbreaking new three-dimensional (3D) bioprinting approach called ... 3D Bio Printer , a state-of-the-art robotic system ... has created a powerful pay-for-service bio-printing model that ...
(Date:2/8/2016)... , Feb. 8, 2016 ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
Breaking Medicine Technology: